查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2023498

藥物發現工具市場分析及預測（至2035年）：類型、產品類型、服務、技術、組件、應用、流程、部署模式、最終用戶

Drug Designing Tools Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Component, Application, Process, Deployment, End User
出版日期: | 出版商: Global Insight Services | 英文 350 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

全球藥物發現工具市場預計將從2025年的40億美元成長到2035年的85億美元，複合年成長率（CAGR）為7.9%。這一成長主要得益於人工智慧和機器學習技術的進步、研發投入的增加以及對個人化醫療日益成長的需求，這些因素共同推動了藥物發現效率的提升和上市時間的縮短。藥物發現工具市場呈現中等程度的整合結構，其主要細分市場包括分子建模軟體（約佔35%的市場佔有率）、基於結構的藥物發現工具（約佔30%）和基於配體的藥物發現工具（約佔20%）。主要應用領域包括藥物研發、生物技術和學術研究。人工智慧和機器學習在藥物發現過程中的日益普及是推動該市場成長的主要因素。從數量上看，軟體安裝量和訂閱量都在穩步成長，反映出市場對先進藥物發現解決方案的需求不斷成長。

競爭格局由全球性和區域性公司並存，其中 Schrodinger, Inc. 和 Certara, Inc. 等公司扮演著重要角色。創新蓬勃發展，各公司大力投資研發，以提升其工具的功能。為拓展技術能力和市場佔有率，併購和策略聯盟屢見不鮮。向雲端解決方案的轉型以及與學術和研究機構合作的加強也是推動市場進一步發展的顯著趨勢。

市場區隔
類型 基於結構的藥物發現、基於配體的藥物發現、基於片段的藥物研發等等。
產品 軟體、資料庫、視覺化工具、建模工具等。
服務 諮詢、培訓和支援、維護、客製化開發等。
科技 機器學習、人工智慧、量子計算、分子建模及其他
成分 演算法、函式庫、框架及其他
應用 腫瘤科、心血管疾病科、神經系統疾病科、感染疾病等。
過程 命中率辨識、先導藥物最適化、目標辨識等等。
實作方法 雲端部署、本地部署、混合部署及其他
最終用戶 製藥公司、生技公司、研究機構、受託研究機構及其他

藥物發現工具市場按類型分類，其中軟體工具在簡化藥物發現流程方面發揮至關重要的作用，佔主導地位。這些工具使研究人員能夠模擬分子間相互作用並預測藥物療效，從而顯著降低傳統方法所需的時間和成本。市場需求主要來自於尋求提高研發效率的製藥和生技公司。人工智慧和機器學習在藥物發現領域日益廣泛的應用是推動該細分市場成長的顯著趨勢。

從技術角度來看，基於結構的藥物發現佔有重要地位。這是因為它能夠精準靶向特定的分子結構，從而提高候選藥物的成功率。這種方法在腫瘤學和神經病學等領域尤其重要，因為在這些領域，理解疾病的分子基礎至關重要。高通量篩檢和計算化學的融合正在增強這一領域的能力，從而帶來更個人化和有效的治療方案。

在應用方面，小分子藥物的發現和開發仍然是藥物創新的基石，發揮主導作用。這些藥物對於治療包括慢性病和感染疾病的多種疾病至關重要。慢性病的增加以及對更具針對性的治療方法的需求日益成長，推動了該領域的需求。此外，對罕見疾病和孤兒藥物的日益關注也擴大了藥物發現工具的應用範圍。

在終端用戶中，製藥公司是藥物設計工具市場的主要驅動力。這是因為製藥公司不斷致力於最佳化其藥物開發平臺。學術和研究機構也透過將這些工具應用於基礎研究和早期藥物發現，做出了重要貢獻。產學合作正在促進創新，旨在加速新療法開發的夥伴關係也不斷增加。

組件部分分為軟體和服務兩大類，其中軟體是主要組件，因為它在促進複雜的藥物研發過程中發揮著至關重要的作用。然而，隨著企業努力最大化其軟體投資的效用，諮詢、培訓和支援等服務也日益受到關注。向雲端解決方案和SaaS（軟體即服務）模式的轉變，透過提高可訪問性和可擴展性，進一步推動了該領域的成長。

區域概覽

北美：北美藥物研發工具市場高度成熟，主要得益於其強大的製藥和生技產業。美國在該地區處於領先地位，這得益於其在研發領域的巨額投資以及先進的醫療保健基礎設施。加拿大也憑藉其蓬勃發展的生技產業和政府的支持政策，為市場做出了貢獻。

歐洲：歐洲市場發展較成熟，德國、英國和瑞士等大型製藥企業的需求強勁。該地區受益於完善的法規結構和對創新藥物研發的重視，這推動了藥物發現工具的發展。

亞太地區：在亞太地區，藥物發現工具市場正快速成長，這主要得益於中國、印度和日本等國不斷加大的醫藥研發投入。在政府政策的支持下，這些國家正大力投資能夠提升藥物發現流程的技術。

拉丁美洲：拉丁美洲市場尚處於起步階段，其中巴西和墨西哥貢獻顯著。該地區的製藥業正在蓬勃發展，這主要得益於人們對改善醫療保健日益成長的興趣以及對藥物研發投入的增加。

中東和非洲：中東和非洲地區尚處於市場發展的早期階段。南非和阿拉伯聯合大公國（阿拉伯聯合大公國）發揮重要作用，兩國不斷增加對醫療基礎設施的投資，以應對區域健康挑戰，並且對生物製藥創新日益關注。

主要趨勢和促進因素

人工智慧與機器學習的融合

將人工智慧 (AI) 和機器學習 (ML) 整合到藥物發現工具中，正在徹底改變市場格局。這些技術能夠快速分析複雜的生物數據、預測分子間相互作用並最佳化候選藥物化合物。 AI 驅動的平台提高了藥物發現過程的效率和準確性，從而降低了傳統方法所需的時間和成本。隨著製藥公司擴大採用 AI 和 ML，對先進藥物發現工具的需求預計將顯著成長。

基於雲端的解決方案

向雲端藥物研發工具的轉型正加速發展，其優勢在於可擴展性、柔軟性和成本效益。雲端平台促進了地理位置分散的研究人員之間的協作，並支援即時數據共用和分析。這一趨勢對缺乏足夠內部運算資源的中小型企業 (SME) 尤其有利。隨著雲端技術的不斷發展，預計將進一步推動藥物研發工具市場的創新和應用。

監管支持和框架

監管環境正朝著更支持創新藥物研發工具的方向發展，監管機構意識到這些技術在簡化藥物開發流程方面的潛力。監管機構正日益提供指導方針和框架，以確保這些工具的安全有效使用。這種支持性的環境鼓勵製藥公司投資先進技術，並促進市場成長。隨著監管的不斷完善，它們將在塑造藥物研發工具的未來方面發揮至關重要的作用。

個人化醫療和標靶治療

個人化醫療和標靶治療的日益普及推動了對先進藥物發現工具的需求。這些工具對於開發針對個別基因譜的客製化治療方法、提高療效和減少副作用至關重要。隨著醫療保健產業向更個人化的模式轉變，對精準高效的藥物發現工具的需求預計將會增加，從而推動市場擴張。

加強合作與夥伴關係

在藥物研發工具市場，製藥公司、技術提供者和學術機構之間的策略聯盟和夥伴關係日益普遍。這些合作有助於共用專業知識、資源和數據，從而加速創新解決方案的發展。相關人員可以相互借鏡優勢，提升自身能力，推動藥物研發的進步。預計這一趨勢將持續下去，推動市場創新和成長。

目錄

第1章摘要整理

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制因素
  • 複合年均成長率：成長分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章：細分市場分析

  • 市場規模及預測：依類型
    • 基於結構的藥物發現
    • 基於配體的藥物發現
    • 基於片段的藥物發現
    • 其他
  • 市場規模及預測：依產品分類
    • 軟體
    • 資料庫
    • 視覺化工具
    • 建模工具
    • 其他
  • 市場規模及預測：依服務分類
    • 諮詢
    • 培訓和支持
    • 維護
    • 合約開發
    • 其他
  • 市場規模及預測：依技術分類
    • 機器學習
    • 人工智慧
    • 量子計算
    • 分子建模
    • 其他
  • 市場規模及預測：依組件分類
    • 演算法
    • 圖書館
    • 框架
    • 其他
  • 市場規模及預測：依應用領域分類
    • 腫瘤學
    • 心血管疾病
    • 神經系統疾病
    • 感染疾病
    • 其他
  • 市場規模及預測：依製程分類
    • 命中識別
    • 先導化合物的最佳化
    • 目標識別
    • 其他
  • 市場規模及預測：依市場細分
    • 基於雲端的
    • 現場
    • 混合
    • 其他
  • 市場規模及預測：依最終用戶分類
    • 製藥公司
    • 生技公司
    • 研究機構
    • 合約研究機構
    • 其他

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地區
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲地區

第6章 市場策略

  • 供需差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 監管概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要企業的策略

第8章：公司簡介

  • Schrodinger
  • Certara
  • Chemical Computing Group
  • BIOVIA
  • OpenEye Scientific Software
  • Molecular Discovery
  • ChemAxon
  • Simulations Plus
  • BioSolveIT
  • Acellera
  • Molsoft
  • Optibrium
  • LeadInvent Technologies
  • Cresset
  • PharmAI
  • Nimbus Therapeutics
  • Atomwise
  • Insilico Medicine
  • Exscientia
  • Cloud Pharmaceuticals

第9章 關於我們

簡介目錄
Product Code: GIS23513

The global drug designing tools market is projected to grow from $4.0 billion in 2025 to $8.5 billion by 2035, at a CAGR of 7.9%. Growth is driven by advancements in AI and machine learning, increasing R&D investments, and the rising demand for personalized medicine, which enhance drug discovery efficiency and reduce time-to-market. The Drug Designing Tools Market is characterized by a moderately consolidated structure, with the top segments including molecular modeling software (approximately 35% market share), structure-based drug design tools (around 30%), and ligand-based drug design tools (about 20%). Key applications include pharmaceutical research, biotechnology, and academic research. The market is driven by the increasing adoption of AI and machine learning in drug discovery processes. In terms of volume, the market is witnessing a steady increase in software installations and subscriptions, reflecting the growing demand for advanced drug design solutions.

The competitive landscape features a mix of global and regional players, with significant contributions from companies like Schrodinger, Inc., and Certara, Inc. The degree of innovation is high, with companies investing heavily in R&D to enhance the capabilities of their tools. Mergers and acquisitions, along with strategic partnerships, are prevalent as companies aim to expand their technological capabilities and market reach. The trend towards cloud-based solutions and collaborations with academic institutions and research organizations is also notable, driving further advancements in the market.

Market Segmentation
TypeStructure-Based Drug Design, Ligand-Based Drug Design, Fragment-Based Drug Design, Others
ProductSoftware, Databases, Visualization Tools, Modeling Tools, Others
ServicesConsulting, Training and Support, Maintenance, Custom Development, Others
TechnologyMachine Learning, Artificial Intelligence, Quantum Computing, Molecular Modeling, Others
ComponentAlgorithms, Libraries, Frameworks, Others
ApplicationOncology, Cardiovascular Diseases, Neurological Disorders, Infectious Diseases, Others
ProcessHit Identification, Lead Optimization, Target Identification, Others
DeploymentCloud-Based, On-Premise, Hybrid, Others
End UserPharmaceutical Companies, Biotechnology Companies, Research Institutes, Contract Research Organizations, Others

The drug designing tools market is segmented by type, with software tools dominating due to their critical role in streamlining the drug discovery process. These tools enable researchers to simulate molecular interactions and predict drug efficacy, significantly reducing the time and cost associated with traditional methods. The demand is primarily driven by pharmaceutical and biotechnology companies seeking to enhance their R&D efficiency. The increasing adoption of AI and machine learning in drug design is a notable trend, further propelling the growth of this segment.

In terms of technology, structure-based drug design holds a significant share, as it allows for precise targeting of specific molecular structures, thereby improving the success rate of drug candidates. This approach is particularly favored in oncology and neurology, where understanding the molecular basis of diseases is crucial. The integration of high-throughput screening and computational chemistry is enhancing the capabilities of this segment, leading to more personalized and effective therapeutic solutions.

The application segment is led by the discovery and development of small molecule drugs, which remain the cornerstone of pharmaceutical innovation. These drugs are essential for treating a wide range of diseases, including chronic and infectious conditions. The rise in chronic diseases and the need for more targeted therapies are driving demand in this segment. Additionally, the growing focus on rare diseases and orphan drugs is expanding the application scope of drug designing tools.

Among end users, pharmaceutical companies are the primary drivers of the drug designing tools market, as they continuously seek to optimize their drug development pipelines. Academic and research institutions also contribute significantly, using these tools for basic research and early-stage drug discovery. The collaboration between industry and academia is fostering innovation, with an increasing number of partnerships aimed at accelerating the development of novel therapeutics.

The component segment is divided into software and services, with software being the dominant component due to its essential role in facilitating complex drug design processes. However, services such as consulting, training, and support are gaining traction, as companies seek to maximize the utility of their software investments. The trend towards cloud-based solutions and software-as-a-service (SaaS) models is enhancing accessibility and scalability, further driving growth in this segment.

Geographical Overview

North America: The drug designing tools market in North America is highly mature, driven by robust pharmaceutical and biotechnology industries. The United States leads the region with significant investments in R&D and advanced healthcare infrastructure. Canada also contributes with its growing biotech sector and supportive government policies.

Europe: Europe exhibits moderate market maturity, with strong demand from pharmaceutical giants in Germany, the UK, and Switzerland. The region benefits from a well-established regulatory framework and a focus on innovative drug development, fostering growth in drug designing tools.

Asia-Pacific: The Asia-Pacific region is experiencing rapid growth in the drug designing tools market, driven by increasing pharmaceutical R&D activities in China, India, and Japan. These countries are investing heavily in technology to enhance drug discovery processes, supported by favorable government initiatives.

Latin America: The market in Latin America is emerging, with Brazil and Mexico as notable contributors. The region's pharmaceutical industry is expanding, driven by a growing focus on healthcare improvements and increasing investments in drug research and development.

Middle East & Africa: The Middle East & Africa region is in the nascent stage of market development. South Africa and the UAE are key players, with growing investments in healthcare infrastructure and a rising interest in biopharmaceutical innovations to address regional health challenges.

Key Trends and Drivers

AI and Machine Learning Integration

The integration of artificial intelligence (AI) and machine learning (ML) in drug designing tools is revolutionizing the market. These technologies enable the rapid analysis of complex biological data, predicting molecular interactions, and optimizing drug candidates. AI-driven platforms are enhancing the efficiency and accuracy of drug discovery processes, reducing time and costs associated with traditional methods. As pharmaceutical companies increasingly adopt AI and ML, the demand for advanced drug designing tools is expected to grow significantly.

Cloud-Based Solutions

The shift towards cloud-based drug designing tools is gaining momentum, offering scalability, flexibility, and cost-effectiveness. Cloud platforms facilitate collaboration among researchers across different geographies, enabling real-time data sharing and analysis. This trend is particularly beneficial for small and medium-sized enterprises (SMEs) that lack extensive in-house computational resources. As cloud technology continues to evolve, it is expected to drive further innovation and adoption in the drug designing tools market.

Regulatory Support and Frameworks

The regulatory landscape is becoming more supportive of innovative drug designing tools, with agencies recognizing the potential of technology to streamline drug development. Regulatory bodies are increasingly providing guidelines and frameworks to ensure the safe and effective use of these tools. This supportive environment encourages pharmaceutical companies to invest in advanced technologies, fostering market growth. As regulations continue to evolve, they are likely to play a pivotal role in shaping the future of drug designing tools.

Personalized Medicine and Targeted Therapies

The growing focus on personalized medicine and targeted therapies is driving the demand for sophisticated drug designing tools. These tools are essential for developing treatments tailored to individual genetic profiles, improving efficacy and reducing adverse effects. As the healthcare industry shifts towards more personalized approaches, the need for precise and efficient drug designing tools is expected to increase, supporting market expansion.

Increased Collaboration and Partnerships

Strategic collaborations and partnerships between pharmaceutical companies, technology providers, and academic institutions are becoming more prevalent in the drug designing tools market. These collaborations facilitate the sharing of expertise, resources, and data, accelerating the development of innovative solutions. By leveraging each other's strengths, stakeholders can enhance their capabilities and drive advancements in drug discovery. This trend is expected to continue, fostering innovation and growth in the market.

Research Scope

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Component
  • 2.6 Key Market Highlights by Application
  • 2.7 Key Market Highlights by Process
  • 2.8 Key Market Highlights by Deployment
  • 2.9 Key Market Highlights by End User

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Structure-Based Drug Design
    • 4.1.2 Ligand-Based Drug Design
    • 4.1.3 Fragment-Based Drug Design
    • 4.1.4 Others
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Software
    • 4.2.2 Databases
    • 4.2.3 Visualization Tools
    • 4.2.4 Modeling Tools
    • 4.2.5 Others
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Consulting
    • 4.3.2 Training and Support
    • 4.3.3 Maintenance
    • 4.3.4 Custom Development
    • 4.3.5 Others
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Machine Learning
    • 4.4.2 Artificial Intelligence
    • 4.4.3 Quantum Computing
    • 4.4.4 Molecular Modeling
    • 4.4.5 Others
  • 4.5 Market Size & Forecast by Component (2020-2035)
    • 4.5.1 Algorithms
    • 4.5.2 Libraries
    • 4.5.3 Frameworks
    • 4.5.4 Others
  • 4.6 Market Size & Forecast by Application (2020-2035)
    • 4.6.1 Oncology
    • 4.6.2 Cardiovascular Diseases
    • 4.6.3 Neurological Disorders
    • 4.6.4 Infectious Diseases
    • 4.6.5 Others
  • 4.7 Market Size & Forecast by Process (2020-2035)
    • 4.7.1 Hit Identification
    • 4.7.2 Lead Optimization
    • 4.7.3 Target Identification
    • 4.7.4 Others
  • 4.8 Market Size & Forecast by Deployment (2020-2035)
    • 4.8.1 Cloud-Based
    • 4.8.2 On-Premise
    • 4.8.3 Hybrid
    • 4.8.4 Others
  • 4.9 Market Size & Forecast by End User (2020-2035)
    • 4.9.1 Pharmaceutical Companies
    • 4.9.2 Biotechnology Companies
    • 4.9.3 Research Institutes
    • 4.9.4 Contract Research Organizations
    • 4.9.5 Others

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Component
      • 5.2.1.6 Application
      • 5.2.1.7 Process
      • 5.2.1.8 Deployment
      • 5.2.1.9 End User
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Component
      • 5.2.2.6 Application
      • 5.2.2.7 Process
      • 5.2.2.8 Deployment
      • 5.2.2.9 End User
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Component
      • 5.2.3.6 Application
      • 5.2.3.7 Process
      • 5.2.3.8 Deployment
      • 5.2.3.9 End User
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Component
      • 5.3.1.6 Application
      • 5.3.1.7 Process
      • 5.3.1.8 Deployment
      • 5.3.1.9 End User
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Component
      • 5.3.2.6 Application
      • 5.3.2.7 Process
      • 5.3.2.8 Deployment
      • 5.3.2.9 End User
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Component
      • 5.3.3.6 Application
      • 5.3.3.7 Process
      • 5.3.3.8 Deployment
      • 5.3.3.9 End User
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Component
      • 5.4.1.6 Application
      • 5.4.1.7 Process
      • 5.4.1.8 Deployment
      • 5.4.1.9 End User
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Component
      • 5.4.2.6 Application
      • 5.4.2.7 Process
      • 5.4.2.8 Deployment
      • 5.4.2.9 End User
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Component
      • 5.4.3.6 Application
      • 5.4.3.7 Process
      • 5.4.3.8 Deployment
      • 5.4.3.9 End User
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Component
      • 5.4.4.6 Application
      • 5.4.4.7 Process
      • 5.4.4.8 Deployment
      • 5.4.4.9 End User
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Component
      • 5.4.5.6 Application
      • 5.4.5.7 Process
      • 5.4.5.8 Deployment
      • 5.4.5.9 End User
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Component
      • 5.4.6.6 Application
      • 5.4.6.7 Process
      • 5.4.6.8 Deployment
      • 5.4.6.9 End User
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Component
      • 5.4.7.6 Application
      • 5.4.7.7 Process
      • 5.4.7.8 Deployment
      • 5.4.7.9 End User
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Component
      • 5.5.1.6 Application
      • 5.5.1.7 Process
      • 5.5.1.8 Deployment
      • 5.5.1.9 End User
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Component
      • 5.5.2.6 Application
      • 5.5.2.7 Process
      • 5.5.2.8 Deployment
      • 5.5.2.9 End User
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Component
      • 5.5.3.6 Application
      • 5.5.3.7 Process
      • 5.5.3.8 Deployment
      • 5.5.3.9 End User
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Component
      • 5.5.4.6 Application
      • 5.5.4.7 Process
      • 5.5.4.8 Deployment
      • 5.5.4.9 End User
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Component
      • 5.5.5.6 Application
      • 5.5.5.7 Process
      • 5.5.5.8 Deployment
      • 5.5.5.9 End User
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Component
      • 5.5.6.6 Application
      • 5.5.6.7 Process
      • 5.5.6.8 Deployment
      • 5.5.6.9 End User
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Component
      • 5.6.1.6 Application
      • 5.6.1.7 Process
      • 5.6.1.8 Deployment
      • 5.6.1.9 End User
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Component
      • 5.6.2.6 Application
      • 5.6.2.7 Process
      • 5.6.2.8 Deployment
      • 5.6.2.9 End User
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Component
      • 5.6.3.6 Application
      • 5.6.3.7 Process
      • 5.6.3.8 Deployment
      • 5.6.3.9 End User
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Component
      • 5.6.4.6 Application
      • 5.6.4.7 Process
      • 5.6.4.8 Deployment
      • 5.6.4.9 End User
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Component
      • 5.6.5.6 Application
      • 5.6.5.7 Process
      • 5.6.5.8 Deployment
      • 5.6.5.9 End User

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Schrodinger
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Certara
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Chemical Computing Group
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 BIOVIA
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 OpenEye Scientific Software
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Molecular Discovery
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 ChemAxon
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Simulations Plus
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 BioSolveIT
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Acellera
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Molsoft
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Optibrium
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 LeadInvent Technologies
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Cresset
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 PharmAI
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Nimbus Therapeutics
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Atomwise
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Insilico Medicine
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Exscientia
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Cloud Pharmaceuticals
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us